Founders Financial Securities LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Key Points

• Founders Financial Securities acquired 8,667 Halozyme shares worth approximately $957,000 in the third quarter. Institutional investors and hedge funds collectively own 97.79% of the company.
• Analyst sentiment is broadly positive, with an average rating of “Moderate Buy” and an average price target of $99.55; HC Wainwright and Stifel Nicolaus set targets of $130.
• Halozyme exceeded quarterly expectations, reporting $2.28 in earnings per share and $481 million in revenue, up 47.7% year over year. Insiders sold $13.5 million of stock over the past 90 days, including 20,000 shares sold by CEO Helen Torley.

Founders Financial Securities LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 8,667 shares of the biopharmaceutical company's stock, valued at approximately $957,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Hilton Head Capital Partners LLC acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at about $33,000. CoreCap Advisors LLC lifted its position in shares of Halozyme Therapeutics by 98.0% during the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 150 shares during the period. MidFirst Bank acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Halozyme Therapeutics in the second quarter valued at $28,000. Finally, Quantbot Technologies LP purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at $30,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HALO has been the topic of a number of research reports. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the company a "buy" rating in a research note on Wednesday, October 7th. Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Weiss Ratings raised Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, August 31st. Stifel Nicolaus set a $130.00 target price on Halozyme Therapeutics in a report on Friday, October 16th. Finally, Zacks Research raised shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $99.55.

Insider Activity

In related news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $109.40, for a total value of $2,188,000.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at $83,995,132. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,852 shares of company stock valued at $13,538,046 in the last ninety days. Company insiders own 2.50% of the company's stock.

Halozyme Therapeutics Stock Down 0.2%

HALO opened at $130.91 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $134.00. The business has a 50-day moving average of $113.70 and a two-hundred day moving average of $83.45. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The stock has a market capitalization of $14.86 billion, a price-to-earnings ratio of 39.08, a price-to-earnings-growth ratio of 0.49 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the firm posted $1.54 EPS. The company's revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.